Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 07 February 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Endocannabinoid system a therapeutic target in liver disease

The most recent issue of Alimentary Pharmacology & Therapeutics reviews the endocannabinoid system in liver disease as a potential therapeutic target.

News image

Endocannabinoids are a family of potent lipid-soluble molecules, acting on the cannabinoid receptors that mediate the effects of marijuana.

The cannabinoid receptors, endocannabinoids and the enzymes involved in their synthesis and degradation are located in the brain and peripheral tissues, including the liver.

Dr Aloysius and colleagues from New York, USA reviewed the current understanding of the role of the endocannabinoid system in liver disease-associated pathophysiological conditions, and drugs targeting the endocannabinoid system as therapy for liver disease.

Original articles and reviews were used to summarize the relevant pre-clinical, and clinical research findings relating to this topic.

Adverse events led to withdrawal of marketing approval
Alimentary Pharmacology & Therapeutics

The researchers found that endocannabinoid system as a whole plays an important role in liver diseases, and related pathophysiological conditions.

The research team reported that pharmacological targeting of the endocannabinoid system has had success as treatment for patients with liver disease, but adverse events led to withdrawal of marketing approval.
 
However, the team noted an optimism over novel therapeutics targeting the endocannabinoid system currently in the pre-clinical stage of development.

Dr Aloysius' team comments, "The endocannabinoid system plays an important role in the pathophysiology of liver disease and its associated conditions."

"While some drugs targeting the endocannabinoid system have deleterious neurological adverse events, there is promise for a newer generation of therapies that do not cross the blood–brain barrier."

Aliment Pharmacol Ther 2014: 39(8): 790–801
24 March 2014

Go to top of page Email this page Email this page to a colleague

 05 February 2016 
Methotrexate and remission in ulcerative colitis
 05 February 2016 
Helicobacter cinaedi bacteremia
 05 February 2016 
Treatment for ileal pouch-anal anastomosis for Crohn’s colitis
 04 February 2016 
Diabetes and liver cancer
 04 February 2016 
Colorectal cancer screening
 04 February 2016 
H. pylori and coronary heart disease 
 03 February 2016 
Acute diverticulitis and IBS 
 03 February 2016 
Microbiota of the colonic mucosa and chronic constipation
 03 February 2016 
Guidelines for chronic pancreatitis
 02 February 2016 
Ramosetron and IBS-diarrhea
 02 February 2016 
IBD emergency department visits
 02 February 2016 
Probiotics for H. pylori management
 01 February 2016 
Managing HBV in pregnancy
 01 February 2016 
Depressive symptoms in IBD 
 01 February 2016 
Obesity and hepatocellular carcinoma risk
 29 January 2016 
Colorectal cancer after colonoscopy
 29 January 2016 
Acute diverticulitis in immunosuppressed patients
 29 January 2016 
Vitamin D and colorectal cancer risk
 28 January 2016 
Tissue anti-TNF drug levels and IBD
 28 January 2016 
First line treatment of H. pylori infection
 28 January 2016 
Tetracycline for rosacea increases the risk of IBD
 27 January 2016 
Steroids in children with Crohn's
 27 January 2016 
Self-management IBS program 
 27 January 2016 
Human gut microbiome in IBD 
 26 January 2016 
Smoking and symptomatic diverticular disease
 26 January 2016 
Step-down therapy in PPI-responsive esophageal eosinophilia 
 26 January 2016 
Diet and IBD risk
 25 January 2016 
IBD monitoring using smartphones
 25 January 2016 
Self-management IBS program
 25 January 2016 
Colorectal cancer after a negative screening sigmoidoscopy
 22 January 2016 
Length of Barrett's and cancer
 22 January 2016 
Psychosocial interventions and alcohol abstinence in chronic liver disease
 22 January 2016 
Helicobacter pylori antibiotic resistance
 21 January 2016 
Increasing adenoma detection rate during colonoscope withdrawal
 21 January 2016 
Microscopic colitis current concepts
 21 January 2016 
Statins as a management strategy for constipation 
 20 January 2016 
Health status after bariatric surgery
 20 January 2016 
Hep E infection in West Africa
 20 January 2016 
Preventing endoscopic bacterial transmission
 19 January 2016 
PPIs and phlebotomy in hereditary hemochromatosis
 19 January 2016 
Predicting liver cirrhosis in Hep C
 19 January 2016 
Frozen vs fresh fecal microbiota transplantation
 18 January 2016 
Hospitalization for diverticulitis in the USA
 18 January 2016 
H. pylori and gastric cancer across Europe
 18 January 2016 
Enteral nutrition in children with Crohn's
 15 January 2016 
Alcohol- and HCV-related hepatocellular carcinoma
 15 January 2016 
Recurrent colonic diverticulitis
 15 January 2016 
Colonic diverticula and colorectal cancer risk
 14 January 2016 
Risk stratification of incidentally discovered gallstones
 14 January 2016 
Treatment of refractory cholestatic pruritus
 14 January 2016 
Colonic diverticula and colorectal cancer risk 
 13 January 2016 
C-section delivery and IBD risk
 13 January 2016 
Primary biliary cholangitis treatment with incomplete UDCA response
 13 January 2016 
Colon cancer screening rates 
 12 January 2016 
Eosinophilic esophagitis endoscopic reference score
 12 January 2016 
Web-based tool for Crohn's disease
 12 January 2016 
IBD patients willingnes to accept medication risk
 11 January 2016 
HCV and increased cardiovascular mortality
 11 January 2016 
Urinary tract cancers in IBD
 11 January 2016 
Race and eosinophilic esophagitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us